Attached files
| file | filename |
|---|---|
| EX-31.2 - GENEREX BIOTECHNOLOGY CORP | v203807_ex31-2.htm |
| EX-31.1 - GENEREX BIOTECHNOLOGY CORP | v203807_ex31-1.htm |
| 10-K/A - GENEREX BIOTECHNOLOGY CORP | v203807_10ka.htm |
Exhibit
32
CERTIFICATIONS
Pursuant
to Section 906 of the Public Company Accounting Reform and Investor Protection
Act of 2002 (18 U.S.C. ss. 1350, as adopted), Mark A. Fletcher, Interim Chief
Executive Officer and President of Generex Biotechnology Corporation (the
"Company"), and Rose C. Perri, Chief Financial Officer of the Company, each
hereby certifies that, to the best of his/her knowledge:
1. This
Amendment No. 1 to the Company's Annual Report on Form 10-K for the period ended
July 31, 2010 to which this Certification is attached as Exhibit 32 (the
"Report") fully complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934, as amended; and
2. The
information contained in the Report fairly presents, in all material respects,
the financial condition and results of operations of the Company at the end of
the period covered by the Report.
|
DATE:
November 24, 2010
|
By: /s/ Mark A. Fletcher
|
|
|
Mark
A. Fletcher
|
||
|
Interim
President & Chief Executive Officer
|
||
|
(Principal
Executive Officer)
|
||
|
DATE:
November 24, 2010
|
By: /s/ Rose C. Perri
|
|
|
Rose
C. Perri
|
||
|
Chief
Financial Officer
|
||
|
(Principal
Financial and Accounting
Officer)
|